Valuation: Soligenix, Inc.

Market Cap 6.08M 5.33M 4.91M 4.6M 8.62M 573M 8.8M 59.04M 22.85M 283M 22.82M 22.32M 983M P/E 2026 *
-0.46x
P/E 2027 * -0.61x
Enterprise Value 6.08M 5.33M 4.91M 4.6M 8.62M 573M 8.8M 59.04M 22.85M 283M 22.82M 22.32M 983M EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.89%
Yield 2026 *
-
Yield 2027 * -
1 day+3.80%
1 week+2.63%
Current month-54.95%
1 month-57.84%
3 months-63.72%
6 months-70.07%
Current year-69.40%
1 week 0.38
Extreme 0.38
0.41
1 month 0.37
Extreme 0.37
0.89
Current year 0.28
Extreme 0.28
1.49
1 year 0.28
Extreme 0.28
6.23
3 years 0.28
Extreme 0.28
32
5 years 0.28
Extreme 0.28
316.8
10 years 0.28
Extreme 0.28
2,040
Manager TitleAgeSince
Chief Executive Officer 59 01/08/2006
Director of Finance/CFO 53 11/09/2019
Chief Tech/Sci/R&D Officer - 11/06/2026
Director TitleAgeSince
Chairman 59 08/10/2009
Director/Board Member 67 01/03/2009
Director/Board Member 80 01/10/2009
Date Insider Type Main position Quantity % Market Cap.
12-11Free

Chief Technology Officer

10,000 0.0991%
12-11Free

Chief Technology Officer

100,000 0.9915%
12-11Free

Chief Financial Officer

100,000 0.9915%
Change 5-day change 1-year change 3-year change Capi.($)
+3.80%+2.63%-69.85%-96.45% 6.08M
-0.41%-1.86%+66.28%+120.74% 55.63B
+0.82%+15.05%+79.52%+88.67% 52.25B
+1.36%+0.36%-14.52%-14.67% 23.07B
-1.04%+7.91%+3.91%+413.05% 22.41B
+6.78%+14.77%+37.54%-1.86% 17.32B
+0.35%+3.26%+30.00%-32.56% 15.94B
+2.89%+5.51%+25.42%+188.41% 13.77B
-3.35%+8.96%+134.32%+282.61% 13.47B
+4.21%+11.01%+33.13% - 12.43B
Average +1.54%+4.56%+32.58%+105.33% 22.63B
Weighted average by Cap. +0.87%+5.13%+49.91%+122.11%

Financials

2026 *2027 *
Net sales - -
Net income -12.4M -10.87M -10.02M -9.38M -17.59M -1.17B -17.96M -120M -46.61M -578M -46.56M -45.55M -2B -13.3M -11.66M -10.75M -10.06M -18.87M -1.25B -19.26M -129M -49.99M -620M -49.94M -48.85M -2.15B
Net Debt - -
Logo Soligenix, Inc.
Soligenix, Inc. is a late-stage biopharmaceutical company, which is focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company’s segments include Specialized Biotherapeutics, and Public Health Solutions. Its Specialized BioTherapeutics business segment is engaged in developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious diseases and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2).
Employees
14
Date Price Change Volume
26/06/26 $0.4100 +3.80% 657,305
25/06/26 $0.3950 +1.02% 920,450
24/06/26 $0.3910 +2.62% 982,586
23/06/26 $0.3810 -2.31% 743,461
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.4100USD
Average target price
1.750USD
Spread / Average Target
+326.83%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SNGX Stock